Baxter International Inc.

79.38-0.6600-0.82%Vol 101.35K1Y Perf -11.28%
Jan 19th, 2021 09:45 DELAYED
BID79.36 ASK79.42
Open80.37 Previous Close80.04
Pre-Market80.16 After-Market-
 0.12 0.15%  - -
Target Price
94.64 
Analyst Rating
Moderate Buy 1.60
Potential %
18.49 
Finscreener Ranking
★★★★     53.30
Insiders Trans % 3/6/12 mo.
-/-100/-91 
Value Ranking
★★★★     56.66
Insiders Value % 3/6/12 mo.
-/-100/-92 
Growth Ranking
★★★★     60.33
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-91 
Income Ranking
★★+     44.95
Market Cap40.55B 
Earnings Rating
Sell
Price Range Ratio 52W %
39.40 
Earnings Date
4th Feb 2021

Today's Price Range

79.3680.65

52W Range

69.1095.19

5 Year PE Ratio Range

4.9072.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-0.65%
1 Month
-1.01%
3 Months
-1.10%
6 Months
-8.03%
1 Year
-11.28%
3 Years
14.33%
5 Years
127.01%
10 Years
232.01%

TickerPriceChg.Chg.%
BAX79.38-0.6600-0.82
AAPL127.930.79000.62
GOOG1 754.8318.64001.07
MSFT213.640.99000.47
XOM48.760.87001.82
WFC32.860.82002.56
JNJ161.341.04000.65
FB254.302.94001.17
GE11.630.30002.65
JPM139.290.65000.47
Financial StrengthValueIndustryS&P 500US Markets
1.90
2.60
0.42
0.81
7.00
Leverage Ratio 2.40
ProfitabilityValueIndustryS&P 500US Markets
38.00
8.70
15.80
18.50
11.06
RevenueValueIndustryS&P 500US Markets
8.49B
16.62
-4.16
-4.26
DividendsValueIndustryS&P 500US Markets
1.22
0.98
14.64
-3.43
Payout ratio50.00
Earnings HistoryEstimateReportedSurprise %
Q03 20200.730.8313.70
Q02 20200.710.64-9.86
Q01 20200.730.8212.33
Q04 20190.880.9710.23
Q02 20190.810.899.88
Q01 20190.680.7611.76
Q04 20180.730.786.85
Q03 20180.740.808.11
Earnings Per EndEstimateRevision %Trend
12/2020 QR0.75-13.79Negative
12/2020 FY3.04-0.33Negative
3/2021 QR0.74-10.84Negative
12/2021 FY3.44-4.71Negative
Next Report Date4th Feb 2021
Estimated EPS Next Report0.75
Estimates Count10
EPS Growth Next 5 Years %9.20
Volume Overview
Volume101.35K
Shares Outstanding510.82M
Trades Count404
Dollar Volume10.79M
Avg. Volume2.45M
Avg. Weekly Volume2.41M
Avg. Monthly Volume2.24M
Avg. Quarterly Volume3.09M

Baxter International Inc. (NYSE: BAX) stock closed at 80.04 per share at the end of the most recent trading day (a -0.01% change compared to the prior day closing price) with a volume of 1.65M shares and market capitalization of 40.55B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 50000 people. Baxter International Inc. CEO is Jose E. Almeida.

The one-year performance of Baxter International Inc. stock is -11.28%, while year-to-date (YTD) performance is -0.25%. BAX stock has a five-year performance of 127.01%. Its 52-week range is between 69.1 and 95.19, which gives BAX stock a 52-week price range ratio of 39.40%

Baxter International Inc. currently has a PE ratio of 45.20, a price-to-book (PB) ratio of 4.77, a price-to-sale (PS) ratio of 4.81, a price to cashflow ratio of 20.80, a PEG ratio of 2.32, a ROA of 4.71%, a ROC of 6.94% and a ROE of 10.89%. The company’s profit margin is 11.06%, its EBITDA margin is 15.80%, and its revenue ttm is $8.49 Billion , which makes it $16.62 revenue per share.

Of the last four earnings reports from Baxter International Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.75 for the next earnings report. Baxter International Inc.’s next earnings report date is 04th Feb 2021.

The consensus rating of Wall Street analysts for Baxter International Inc. is Moderate Buy (1.6), with a target price of $94.64, which is +18.49% compared to the current price. The earnings rating for Baxter International Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Baxter International Inc. has a dividend yield of 1.22% with a dividend per share of $0.98 and a payout ratio of 50.00%.

Baxter International Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.87, ATR14 : 6.43, CCI20 : -38.42, Chaikin Money Flow : 538.18, MACD : 0.50, Money Flow Index : 61.17, ROC : 1.06, RSI : 52.54, STOCH (14,3) : 31.65, STOCH RSI : 0.00, UO : 54.56, Williams %R : -68.35), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Baxter International Inc. in the last 12-months were: Albert P L Stroucken (Option Excercise at a value of $104 846), Albert P L Stroucken (Sold 4 320 shares of value $344 027 ), Andrew Frye (Sold 3 742 shares of value $340 522 ), Cristiano Franzi (Option Excercise at a value of $2 899 918), Cristiano Franzi (Sold 46 600 shares of value $4 083 879 ), Giuseppe Accogli (Option Excercise at a value of $3 552 302), Giuseppe Accogli (Sold 72 341 shares of value $6 148 985 ), James R. Gavin (Option Excercise at a value of $1 136 578), James R. Gavin (Sold 29 798 shares of value $2 574 732 ), Jeanne K. Mason (Option Excercise at a value of $1 365 819), Jeanne K. Mason (Sold 47 146 shares of value $4 390 608 ), John D. Forsyth (Option Excercise at a value of $197 251), John D. Forsyth (Sold 6 310 shares of value $504 863 ), Peter S. Hellman (Sold 0 shares of value $-209 693 ), Peter S. Hellman (Sold 8 640 shares of value $688 284 ), Sean B.W. Martin (Buy at a value of $803 818)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (66.67 %)
10 (66.67 %)
7 (50.00 %)
Moderate Buy
1 (6.67 %)
1 (6.67 %)
1 (7.14 %)
Hold
4 (26.67 %)
4 (26.67 %)
6 (42.86 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.60
Moderate Buy
1.60
Moderate Buy
1.93

Baxter International Inc.

Baxter manufactures medical products across seven major reported business segments. The renal segment (33% of 2018 sales) includes peritoneal dialysis and hemodialysis products for chronically ill patients while its acute therapies segment (5%) offers kidney or other organ support tools in intensive care situations. The medication delivery segment (24% of sales) sells IV pumps, administrative sets, and solutions while its nutrition segment (8% of sales) offers parenteral nutrition therapies. The pharmaceuticals segments (19% of sales) offers injectable drugs, anesthetic gases, and compounding services. The advanced surgery segment (7% of sales) provides hemostastic products and biosurgical sealants. Contract manufacturing rounds out the remaining 5% of sales.

CEO: Jose E. Almeida

Teplephone: +1 224 948-2000

Address: One Baxter Parkway, Deerfield 60015, IL, USA

Number of employees: 50 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

52%48%

Bearish Bullish

59%41%

Bearish Bullish

62%38%

News

Stocktwits